Exelixis, Inc.

NasdaqGS:EXEL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

United States

Market Cap

USD 11.83 B

Share Price

USD 43.37

Avg Daily Volume

3,003,977

Change (1 day)

7.43%

Change (1 year)

95.36%

Change (YTD)

30.24%

Exelixis, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending April 04, 2025: USD 812.84 M

Exelixis, Inc. Free Cash Flow is USD 812.84 M for the Trailing 12 Months (TTM) ending April 04, 2025, a 339.13% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Exelixis, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 29, 2024 was USD 185.10 M, a 56.96% change year over year.
Exelixis, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 117.93 M, a -73.95% change year over year.
Exelixis, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending April 01, 2022 was USD 452.70 M, a 198.79% change year over year.
Exelixis, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending April 02, 2021 was USD 151.51 M, a -62.86% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqGS: EXEL

Exelixis, Inc.

CEO	Dr. Michael M. Morrissey Ph.D.
IPO Date	April 17, 2000
Location	United States
Headquarters	1851 Harbor Bay Parkway
Employees	1,147
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.